In vitro Susceptibility of Geographically and Temporally Distinct Zika Viruses to Favipiravir and Ribavirin

Kuno G. , Chang G.J. , Tsuchiya K.R. , Karabatsos N. , Cropp C.B. Phylogeny of the genus Flavivirus. J Virol 1998; 72: 73–83.

Dick G.W. , Kitchen S.F. , Haddow A.J. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 1952; 46: 509–520.

Duffy M.R. , Chen T.H. , Hancock W.T. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 2009; 360: 2536–2543.

Ioos S. , Mallet H.P. , Leparc Goffart I. , Gauthier V. , Cardoso T. , Herida M. Current Zika virus epidemiology and recent epidemics. Med Mal Infect 2014; 44: 302–307.

Zanluca C. , Melo V.C. , Mosimann A.L. , Santos G.I. , Santos C.N. , Luz K. First report of autochthonous transmission of Zika virus in Brazil. Mem Inst Oswaldo Cruz 2015; 110: 569–572.

World Health Organization. Situation report. Zika virus microcephaly and Guillain-Barre syndrome. (Updated 10 March 2017. Accessed 25 April 2017.) Available from http://www.who.int/emergencies/zika-virus/situation-report/10-march-2017/en/.

Rasmussen S.A. , Jamieson D.J. , Honein M.A. , Petersen L.R. Zika virus and birth defects–reviewing the evidence for causality. N Engl J Med 2016; 374: 1981–1987.

World Health Organization. WHO director-general summarizes the outcome of the emergency committee regarding clusters of microcephaly and Guillain-Barre syndrome. (Accessed 2 February 2016.) Available from http://www.who.int/mediacentre/news/statements/2016/emergency-committee-zika-microcephaly/en.

Gowen B.B. , Wong M.H. , Jung K.H. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007; 51: 3168–3176.

Smither S.J. , Eastaugh L.S. , Steward J.A. , Nelson M. , Lenk R.P. , Lever M.S. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 2014; 104: 153–155.

Morrey J.D. , Taro B.S. , Siddharthan V. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 2008; 80: 377–379.

Julander J.G. , Smee D.F. , Morrey J.D. , Furuta Y. Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res 2009; 82: 169–171.

Jochmans D. , van Nieuwkoop S. , Smits S.L. , Neyts J. , Fouchier R.A. , van den Hoogen B.G. Antiviral activity of favipiravir (T-705) against a broad range of paramyxoviruses in vitro and against human metapneumovirus in hamsters. Antimicrob Agents Chemother 2016; 60: 4620–4629.

Rocha-Pereira J. , Jochmans D. , Dallmeier K. , Leyssen P. , Nascimento M.S. , Neyts J. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 2012; 424: 777–780.

ClinicalTrials.gov. Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults. 8 December 2013. (Accessed 15 September 2015.) Available from https://clinicaltrials.gov/ct2/show/NCT02008344.

Sissoko D. , Laouenan C. , Folkesson E. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 2016; 13: e1001967.

Zmurko J. , Marques R.E. , Schols D. , Verbeken E. , Kaptein S.J. , Neyts J. The viral polymerase inhibitor 7-deaza-2′-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl Trop Dis 2016; 10: e0004695.

Hézode C. , Forestier N. , Dusheiko G. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839–1850.

Cooper A.C. , Banasiak N.C. , Allen P.J. Management and prevention strategies for respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a review of evidence-based practice interventions. Pediatr Nurs 2003; 29: 452–456.

Rattanaburee T. , Junking M. , Panya A. Inhibition of dengue virus production and cytokine/chemokine expression by ribavirin and compound A. Antiviral Res 2015; 124: 83–92.

McCormick J.B. , King I.J. , Webb P.A. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314: 20–26.

De Clercq E. , Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 2016; 29: 695–747.

Kochhar D.M. , Penner J.D. , Knudsen T.B. Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol 1980; 52: 99–112.

Vernekar S.K. , Qiu L. , Zhang J. 5′-Silylated 3′-1,2,3-triazolyl thymidine analogues as inhibitors of West Nile virus and dengue virus. J Med Chem 2015; 58: 4016–4028.

Piret J. , Goyette N. , Boivin G. Novel method based on realtime cell analysis for drug susceptibility testing of herpes simplex virus and human cytomegalovirus. J Clin Microbiol 2016; 54: 2120–2127.

Perreault M. , Maltais R. , Dutour R. , Poirier D. Explorative study on the anticancer activity, selectivity and metabolic stability of related analogs of aminosteroid RM-133. Steroids 2016; 115: 105–113.

Furuta Y. , Gowen B.B. , Takahashi K. , Shiraki K. , Smee D.F. , Barnard D.L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100: 446–454.

Hayden F.G. , Cote K.M. , Douglas R.G. Jr. . Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother 1980; 17: 865–870.

Markland W. , McQuaid T.J. , Jain J. , Kwong A.D. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother 2000; 44: 859–866.

Mentré F. , Taburet A.M. , Guedj J. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis 2015; 15: 150–151.